Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 15, 2021 | June 17, 2021 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 06, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,222 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 19,697 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 18,222 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F3: This award is fully vested in accordance with its terms.
Aquestive Therapeutics, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2031-06-15 | Direct | 20,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,758 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 26,758 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
EyePoint, Inc.
Report date January 06, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,346 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Exercise / conversion · Acquired 75,133 · Balance 294,346 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-06 · Exercise / conversion · Disposed 75,133 · Balance 0 F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 126,889 |
Reported balance
Holding disclosure · report date 2026-01-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 126,889 F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 23, 2026 00:01 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000089 · form4.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:01 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,475 | $36.95 | $54,501.25 |
DisclosureSEC source: 0001520262-26-000089 · form4.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,222 Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:01 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000089 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:01 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000089 · form4.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:01 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000089 · form4.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001450485-26-000009 · form4-05182026_040516.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,758 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,500 | $35.97 | $161,860.95 |
DisclosureSEC source: 0001450485-26-000007 · form4-05152026_040505.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,017 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.55 to $36.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2026 Filed Apr 13, 2026 21:09 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000070 · form4.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,752 Underlying: Ordinary Shares · 3,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. Read SEC document |
| April 11, 2026 Filed Apr 13, 2026 21:09 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 901 | $33.36 | $30,057.36 |
DisclosureSEC source: 0001520262-26-000070 · form4.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,555 Read SEC document |
| April 11, 2026 Filed Apr 13, 2026 21:09 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000070 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:13 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 75,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001450485-26-000005 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 6, 2024. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:13 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 75,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001450485-26-000005 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 12,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001450485-26-000003 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,667 Underlying: Common Stock · 12,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 5, 2025. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 12,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001450485-26-000003 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001450485-26-000003 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 9,300 | $15.11 | $140,477.43 |
DisclosureSEC source: 0001450485-25-000009 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,547 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.36. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. average price. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:09 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 500 | $14.95 | $7,475.00 |
DisclosureSEC source: 0001450485-25-000007 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,847 F1 · price: The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:09 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 200 | $14.95 | $2,990.00 |
DisclosureSEC source: 0001450485-25-000007 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,347 F1 · price: The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005390 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,112 Underlying: Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005390 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 27,270 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 10 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 27,270 Underlying: Common Stock · 27,270 shares Expires 2034-01-04 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 27,270 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 9 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,730 Underlying: Common Stock · 27,270 shares Expires 2034-01-04 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 15,278 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 31,944 Underlying: Common Stock · 15,278 shares Expires 2033-07-10 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 15,278 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,722 Underlying: Common Stock · 15,278 shares Expires 2033-07-10 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 103,308 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 272,358 Underlying: Common Stock · 103,308 shares Expires 2033-01-05 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 103,308 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,442 Underlying: Common Stock · 103,308 shares Expires 2033-01-05 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 200,000 Underlying: Common Stock · 55,000 shares Expires 2032-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 55,000 shares Expires 2032-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 31,165 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 213,700 Underlying: Common Stock · 31,165 shares Expires 2031-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 31,165 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,165 shares Expires 2031-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016202 · form4.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,924 | $30.61 | $58,893.64 |
DisclosureSEC source: 0001127602-25-016202 · form4.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,705 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:31 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016202 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:58 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015541 · form4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:58 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015541 · form4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009809 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,517 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,503 Underlying: Ordinary Shares · 3,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 2,323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 901 | $27.00 | $24,327.00 |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · nonDerivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,616 Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · nonDerivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 558 | $27.00 | $15,066.00 |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,765 Read SEC document |
| April 11, 2025 Filed Apr 14, 2025 21:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 2,323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-012018 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001134 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three annual installments beginning February 9, 2023. F2 · derivative.expiration_date: The restricted stock units vests in three annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001134 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 22:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 12,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001754 · form4.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,726 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on February 4, 2026, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on such date in shares of the Issuer's common stock. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 75,134 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,133 Underlying: Common Stock · 75,134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. F3 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 75,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 12,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,333 Underlying: Common Stock · 12,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 12,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.